Arena and Eisai Resubmit Lorcaserin to FDA

Arena Pharmaceuticals and partner Eisai are optimistic that regulators will approve their obesity drug, lorcaserin, after responding to a rejection issued by the US Food and Drug Administration in October 2010. Arena has submitted their response to the comprehensive reply letter from the Food and Drug Administration which cited a number of reasons for their

Continue Reading